

Amendment

The following listing of claims will replace all prior versions and listings of claims in the application.

**Listing of the Claims:**


1-12. (Cancelled)

13. (Currently Amended) A vaccine for preventing viral infections with influenza virus comprising:

an influenza virus antigen;

a peptide (Peptide A) comprising a sequence  $R_1-XZXZX_NXZX-R_2$ , whereby N is a whole number between 3 and 7, X is a positively charged natural and/or non-natural amino acid residue, Z is an amino acid residue selected from the group consisting of L, V, I, F and/or W, and  $R_1$  and  $R_2$  are independently -H, -NH<sub>2</sub>, -COCH<sub>3</sub>, -COH, a peptide with up to 20 amino acid residues or a peptide reactive group or a peptide linker with or without a peptide;  $X-R_2$  is an amide, ester or thioester of the C-terminal amino acid residue of the peptide; and

an immunostimulatory oligodeoxynucleic acid molecule (I-/U-ODN) having the structure according to the formula (I):



wherein:

R1 is selected from hypoxanthine and uracile;  
any X is O or S;  
any NMP is a 2' deoxynucleoside monophosphate or monothiophosphate, selected from the group consisting of deoxyadenosine-, deoxyguanosine-, deoxyinosine-, deoxycytosine-, deoxyuridine-, deoxythymidine-, 2-methyl-deoxyinosine-, 5-methyl-deoxycytosine-, deoxypseudouridine-, deoxyribosepurine-, 2-amino-deoxyribosepurine-, 6-S-deoxyguanine-, 2-dimethyl-deoxyguanosine- or N-isopentenyl-deoxyadenosine-monophosphate or -monothiophosphate;  
NUC is a 2' deoxynucleoside, selected from the group consisting of deoxyadenosine-, deoxyguanosine-, deoxyinosine-, deoxycytosine-, deoxyinosine-, deoxythymidine-, 2-methyl-deoxyuridine-, 5-methyl-deoxycytosine-, deoxypseudouridine-, deoxyribosepurine-, 2-amino-deoxyribosepurine-, 6-S-deoxyguanine-, 2-dimethyl-deoxyguanosine- or N-isopentenyl-deoxyadenosine;  
a and b are integers from 0 to 100 with the proviso that a + b is between 4 and 150; and  
B and E are common groups for 5' or 3' ends of nucleic acid molecules.

14. (Previously Presented) The vaccine of claim 13, wherein N is 5.
15. (Previously Presented) The vaccine of claim 13, further comprising an  $\text{Al}(\text{OH})_3$  adjuvant.
- 16-17. (Canceled)
18. (Currently Amended) The vaccine of claim [[18]]13, wherein the ~~viral antigen~~ is an influenza antigen ~~further defined as~~ is a haemagglutinin antigen or a neuraminidase antigen.
19. (Previously Presented) The vaccine of claim 13, further comprising a polycationic peptide.
20. (Currently Amended) The vaccine of claim 13, wherein Peptide A is KLKL<sub>5</sub>KLK (SEQ ID NO:6) and the I/U-ODN is oligo d(IC)<sub>13</sub>.

21. (Previously Presented) The vaccine of claim 13, further comprising an oligodeoxynucleotide containing a CpG-motif.

22. (Previously Presented) The vaccine of claim 13, further comprising a polycationic peptide and an oligodeoxynucleotide containing a CpG-motif.

23.-28. (Canceled)